Physicians East, PA

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes4 trials
• Chronic kidney disease2 trials
• High blood pressure2 trials
• Obesity2 trials
• Type 1 diabetes2 trials
• Rheumatoid arthritis1 trial

Phase

• Phase 35 trials
• Phase 1/21 trial
• Phase 21 trial

Status

• Completed4 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Boehringer Ingelheim3 trials
• Alfasigma S.p.A.1 trial
• COUR Pharmaceutical Development Company, Inc.1 trial
• Inversago Pharma Inc.1 trial
• Novo Nordisk A/S1 trial

Running trials

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

  NCT06783309· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

  Contact: Kirsten Goff

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• High blood pressure1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Completed

  Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

  NCT05514548· Phase 2· Inversago Pharma Inc.· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source